Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
JCO Glob Oncol ; 6: 317-330, 2020 11.
Article in English | MEDLINE | ID: mdl-35275745

ABSTRACT

Fertility preservation in the cancer setting, known as oncofertility, is a field that requires cross-disciplinary interaction between physicians, basic scientists, clinical researchers, ethicists, lawyers, educators, and religious leaders. Funded by the National Institutes of Health, the Oncofertility Consortium (OC) was formed to be a scientifically grounded, transparent, and altruistic resource, both intellectual and monetary, for building this new field of practice capable of addressing the unique needs of young patients with cancer. The OC has expanded its attention to include other nonmalignant conditions that can threaten fertility, and the work of the OC now extends around the globe, involving partners who together have created a community of shared effort, resources, and practices. The OC creates materials that are translated, disseminated, and amended by all participants in the field, and local programs of excellence have developed worldwide to accelerate the pace and improve the quality of oncofertility research and practice. Here we review the global oncofertility programs and the capacity building activities that strengthen these research and clinical programs, ultimately improving patient care.

2.
Future Oncol ; 14(29): 3059-3072, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30474429

ABSTRACT

Once unimaginable, fertility management is now a nationally established part of cancer care in institutions, from academic centers to community hospitals to private practices. Over the last two decades, advances in medicine and reproductive science have made it possible for men, women and children to be connected with an oncofertility specialist or offered fertility preservation soon after a cancer diagnosis. The Oncofertility Consortium's National Physicians Cooperative is a large-scale effort to engage physicians across disciplines - oncology, urology, obstetrics and gynecology, reproductive endocrinology, and behavioral health - in clinical and research activities to enable significant progress in providing fertility preservation options to children and adults. Here, we review the structure and function of the National Physicians Cooperative and identify next steps.


Subject(s)
Fertility Preservation/methods , Fertility/physiology , Intersectoral Collaboration , Neoplasms/physiopathology , Physicians/organization & administration , Adult , Antineoplastic Agents/adverse effects , Behavioral Medicine/organization & administration , Child , Disease Progression , Endocrinology/methods , Endocrinology/organization & administration , Female , Fertility/drug effects , Gynecology/methods , Gynecology/organization & administration , Humans , Medical Oncology/methods , Medical Oncology/organization & administration , Neoplasms/complications , Neoplasms/pathology , Neoplasms/therapy , Obstetrics/methods , Obstetrics/organization & administration , Practice Guidelines as Topic , Pregnancy , Quality of Life , Reproductive Medicine/methods , Reproductive Medicine/organization & administration , United States , Urology/methods , Urology/organization & administration
3.
Future Oncol ; 14(4): 363-378, 2018 Feb.
Article in English | MEDLINE | ID: mdl-29345507

ABSTRACT

AIM: To characterize the clinical indications of females (<15 years old) undergoing ovarian tissue cryopreservation (OTC) through the Oncofertility Consortium's National Physicians Cooperative (OC-NPC). PATIENTS & METHODS: The clinical indications of 114 females who underwent OTC were classified, and their incidence was compared with childhood cancer databases. RESULTS: Leukemias/myeloproliferative diseases/myelodysplastic diseases and hemoglobinopathies were the most prevalent oncologic and nononcologic indications for OTC, respectively. The frequencies of malignant bone tumors and soft tissue and other extraosseous sarcomas were higher in the OC-NPC cohort relative to the general population, while CNS/intracranial/intraspinal neoplasms, retinoblastoma and hepatic tumors were lower. CONCLUSION: Those opting for OTC through the OC-NPC are at highest fertility risk, indicating that the appropriate patient populations are being identified. [Formula: see text].


Subject(s)
Fertility Preservation/methods , Neoplasms/epidemiology , Ovary/physiology , Adolescent , Child , Child, Preschool , Cryopreservation/methods , Female , Humans , Laparoscopy , Neoplasms/physiopathology
4.
J Adolesc Young Adult Oncol ; 6(3): 444-449, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28459598

ABSTRACT

PURPOSE: To describe physician attitudes and variations in oncofertility treatment strategies. METHODS: An exploratory online survey administered between December 1, 2014 and January 27, 2015 to 185 members of the National Physicians Cooperative (NPC). RESULTS: Twenty-eight percent (52 of 185) of NPC members responded to the online survey. Fifty percent of respondents were obstetrician-gynecologists working largely in academic medical centers. Thirty-eight percent stated that 14 was the youngest age they felt comfortable performing oocyte retrievals with 35% stating that any age was acceptable as long as they were postpubertal. Short stimulation protocols, utilizing a gonadotropin-releasing hormone (GnRH) antagonist (86%), were more common than long stimulation or microdose Lupron flare protocols (23% and 18%), respectively, which utilize a GnRH agonist. Random start protocols were used by 77% and over 90% perform luteal phase starts. When using random start protocols, 64% use gonadotropins only and 32% start GnRH antagonists alone for several days before starting gonadotropins. Fifty-five percent of physicians were comfortable stimulating ovarian cancer patients only after clearance from an oncologist. Aromatase inhibitors (77%) were significantly more common than tamoxifen (24%) for stimulation in breast cancer patients (p = 0.0006). When considering ovarian stimulation after chemotherapy, 24% expressed comfort only if blood counts are normal, 38% tend to wait 3 months. Regarding experimental treatment, 83% report discussing the use of GnRH agonists alone and 64% of clinics offer ovarian tissue cryopreservation. CONCLUSIONS: This study underlines the wide variation that exists in stimulation and phase start techniques, patient selection, comfort levels, and cancer type-specific decision making.


Subject(s)
Attitude of Health Personnel , Fertility Preservation , Infertility, Female/prevention & control , Practice Patterns, Physicians'/statistics & numerical data , Adult , Female , Fertility Preservation/psychology , Fertility Preservation/statistics & numerical data , Health Knowledge, Attitudes, Practice , Humans , Infertility, Female/psychology , Pregnancy , Surveys and Questionnaires , Young Adult
5.
J Glob Oncol ; 2(2): 83-96, 2016 Apr.
Article in English | MEDLINE | ID: mdl-27284576

ABSTRACT

Fertility preservation in the cancer setting, known as oncofertility, is a field that requires cross-disciplinary interaction between physicians, basic scientists, clinical researchers, ethicists, lawyers, educators, and religious leaders. Funded by the National Institutes of Health, the Oncofertility Consortium (OC) was formed to be a scientifically grounded, transparent, and altruistic resource, both intellectual and monetary, for building this new field of practice capable of addressing the unique needs of young patients with cancer. The OC has expanded its attention to include other nonmalignant conditions that can threaten fertility, and the work of the OC now extends around the globe, involving partners who together have created a community of shared effort, resources, and practices. The OC creates materials that are translated, disseminated, and amended by all participants in the field, and local programs of excellence have developed worldwide to accelerate the pace and improve the quality of oncofertility research and practice. Here we review the global oncofertility programs and the capacity building activities that strengthen these research and clinical programs, ultimately improving patient care.

6.
J Womens Health (Larchmt) ; 24(10): 812-8, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26075731

ABSTRACT

Young women diagnosed with cancer today have a greater chance of long-term survival than ever before. Successful survivorship for this group of patients includes maintaining a high quality of life after a cancer diagnosis and treatment; however, lifesaving treatments such as chemotherapy, radiation, and surgery can impact survivors by impairing reproductive and endocrine health. Studies demonstrate that future fertility is a concern for many women diagnosed with cancer, but physician knowledge and attitudinal barriers can still prevent females from receiving care. Today, fertility preservation is an option for girls and women facing a cancer diagnosis, and emerging research is providing clinicians with an increasing number of reproductive and hormonal management tools. Physicians can play an important role in fertility by working closely with oncologists, providing patients with information about fertility preservation options prior to the start of cancer treatment, monitoring reproductive capacity after treatment, and working with cancer survivors to explore potential avenues to parenthood.


Subject(s)
Fertility Preservation , Infertility, Female/therapy , Neoplasms/therapy , Female , Health Knowledge, Attitudes, Practice , Humans , Neoplasms/diagnosis , Quality of Life , Survivors
SELECTION OF CITATIONS
SEARCH DETAIL
...